<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580251</url>
  </required_header>
  <id_info>
    <org_study_id>CHIR-05-IMTAD</org_study_id>
    <nct_id>NCT04580251</nct_id>
  </id_info>
  <brief_title>Ideal Marker for Targeted Axillary Dissection</brief_title>
  <acronym>IMTAD</acronym>
  <official_title>Ideal Marker for Targeted Axillary Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Silesian Hospital in Opava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Masaryk Memorial Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EUC Clinic in Zlín</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for the Care of Mother and Child, Prague, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre prospective comparative study, comparing the use of various markers (magnetic&#xD;
      marker Magseed, iodine seed 125I, carbon suspension) for marking a pathological lymph node in&#xD;
      patients with breast carcinoma prior to neoadjuvant therapy and subsequent surgical treatment&#xD;
      consisting of targeted axillary dissection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two basic aims of the study&#xD;
&#xD;
        1. Prospective comparison of the reliability and accuracy of individual markers used for&#xD;
           marking of a pathological axillary lymph node with subsequent targeted axillary&#xD;
           dissection.&#xD;
&#xD;
        2. Comparison of the number of complications during localizing and detection of individual&#xD;
           markers and postoperative complications.&#xD;
&#xD;
      In individual collaborating centers, these markers are commonly used in clinical practice for&#xD;
      marking of a pathological lymph node in patients with breast carcinoma. The usual standard of&#xD;
      practice and treatment will not be changed in any way; the patients will only be&#xD;
      prospectively followed. The study will bring an answer to the question of which marker is the&#xD;
      best for marking lymph nodes.&#xD;
&#xD;
      Apart from the basic demographic and other data (patient age, side of the body, size and&#xD;
      characteristics of the tumor (typing, grading, staging), type and time of surgery, the&#xD;
      incidence of complications during implantation or detection of the marker, number of lymph&#xD;
      nodes, complications after surgery, and the final histological findings, also the following&#xD;
      outcome measures will be observed:&#xD;
&#xD;
        -  depth of marker implantation (measured in mm)&#xD;
&#xD;
        -  marker migration (measured in mm)&#xD;
&#xD;
        -  success-rate of resection of the marked lymph node - assessment, whether the lymph node&#xD;
           was removed (yes/no) using the respective marker, expressed in percent of successful&#xD;
           removal for the respective marker&#xD;
&#xD;
        -  time from localizing the pathological lymph node using the marker to surgery (measured n&#xD;
           days)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Depth of marker implantation</measure>
    <time_frame>During surgery/intervention</time_frame>
    <description>The depth of marker implantation will be assessed and measured in millimetres</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Marker migration</measure>
    <time_frame>During surgery/intervention</time_frame>
    <description>Marker migration will be assessed and measured in millimetres</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success-rate of resection of the marked lymph node</measure>
    <time_frame>1 month</time_frame>
    <description>Assessment, whether the lymph node was removed (yes/no) using the respective marker, expressed in percent of successful removal for the respective marker.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time from localizing the pathological lymph node using the marker to surgery</measure>
    <time_frame>1 month</time_frame>
    <description>The time from localizing the pathological lymph node using the marker to surgery will be analysed and measured in days</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Magnetic marker Magseed</arm_group_label>
    <description>Patients in whom the magnetic marker Magseed is used will be enrolled in this study arm and will undergo targeted axillary dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iodine seed 125I marker</arm_group_label>
    <description>Patients in whom the iodine seed 125I marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbon suspension</arm_group_label>
    <description>Patients in whom the carbon suspension marker is used will be enrolled in this study arm and will undergo targeted axillary dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted axillary dissection</intervention_name>
    <description>The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)</description>
    <arm_group_label>Carbon suspension</arm_group_label>
    <arm_group_label>Iodine seed 125I marker</arm_group_label>
    <arm_group_label>Magnetic marker Magseed</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breast cancer confirmed with a biopsy, indicated for neoadjuvant chemotherapy&#xD;
        and axillary dissection, in whom pathological lymph nodes have been marked using one of the&#xD;
        three examined and compared markers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of breast cancer, confirmed with a biopsy&#xD;
&#xD;
          -  indication of neoadjuvant therapy&#xD;
&#xD;
          -  biopsy of pathologically enlarged axillary lymph node and marking of the lymph node&#xD;
             using one of the markers before neoadjuvant chemotherapy&#xD;
&#xD;
          -  surgical treatment after neoadjuvant chemotherapy (targeted axillary dissection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal to participate in the study&#xD;
&#xD;
          -  another treatment protocol, which does not include targeted axillary dissection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Žatecký, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Silesian Hospital in Opava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petr Vávra, Ass.Prof.,MD,PhD</last_name>
    <phone>0042059737</phone>
    <phone_ext>2544</phone_ext>
    <email>veda@fno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiří Hynčica</last_name>
    <phone>0042059737</phone>
    <phone_ext>2587</phone_ext>
    <email>jiri.hyncica@fno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Silesian Hospital in Opava</name>
      <address>
        <city>Opava</city>
        <state>Moravian-Silesian Region</state>
        <zip>74601</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Žatecký, MD</last_name>
      <phone>+420776193203</phone>
      <email>janzatecky.jz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jan Žatecký, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Vávra, Ass.Prof.,MD,PhD</last_name>
      <phone>0042059737</phone>
      <phone_ext>2544</phone_ext>
      <email>veda@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Jiří Hynčica</last_name>
      <phone>0042059737</phone>
      <phone_ext>2587</phone_ext>
      <email>jiri.hyncica@fno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Otakar Kubala, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for the Care of Mother and Child, Prague, Czech Republic</name>
      <address>
        <city>Praha</city>
        <state>Prague</state>
        <zip>14700</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel Rauš, MD</last_name>
      <phone>00420296511</phone>
      <phone_ext>315</phone_ext>
    </contact>
    <investigator>
      <last_name>Karel Rauš, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masaryk Memorial Cancer Institute</name>
      <address>
        <city>Brno</city>
        <state>South Moravian Region</state>
        <zip>65653</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oldřich Coufal, Ass.Prof.,MD,PhD</last_name>
      <phone>0042054313</phone>
      <phone_ext>5249</phone_ext>
      <email>coufal@mou.cz</email>
    </contact>
    <investigator>
      <last_name>Oldřich Coufal, Ass.Prof.,MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucie Gabrielová, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ondřej Zapletal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EUC Clinic in Zlín</name>
      <address>
        <city>Zlín</city>
        <state>Zlín Region</state>
        <zip>76001</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiří Gatěk, Ass.Prof.,MD,PhD</last_name>
      <phone>+420571857</phone>
      <phone_ext>111</phone_ext>
      <email>info.zlin@eucklinika.cz</email>
    </contact>
    <investigator>
      <last_name>Jiří Gatěk, Ass.Prof.,MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>axillary dissection</keyword>
  <keyword>Magseed marker</keyword>
  <keyword>iodine seed</keyword>
  <keyword>carbon suspension</keyword>
  <keyword>axillary lymph node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data may be made available to other researchers upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

